X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (412) 412
cardiac & cardiovascular systems (345) 345
male (310) 310
female (309) 309
aged (283) 283
middle aged (239) 239
abridged index medicus (192) 192
treatment outcome (182) 182
risk factors (177) 177
atrial fibrillation (153) 153
stroke (152) 152
mortality (128) 128
heart attacks (127) 127
acute coronary syndromes (118) 118
cardiovascular (118) 118
double-blind method (108) 108
myocardial infarction (107) 107
clopidogrel (103) 103
clinical trials (98) 98
follow-up studies (95) 95
anticoagulants (91) 91
drug therapy (89) 89
outcomes (89) 89
care and treatment (88) 88
risk (86) 86
stroke - prevention & control (80) 80
medical and health sciences (77) 77
medicin och hälsovetenskap (77) 77
peripheral vascular disease (76) 76
warfarin (75) 75
prospective studies (73) 73
cardiology (72) 72
coronary heart disease (72) 72
anticoagulants - therapeutic use (70) 70
time factors (70) 70
analysis (68) 68
hemorrhage - chemically induced (68) 68
prognosis (68) 68
atrial fibrillation - complications (67) 67
atrial fibrillation - drug therapy (67) 67
platelet aggregation inhibitors - therapeutic use (67) 67
electrocardiography (66) 66
aged, 80 and over (64) 64
patients (64) 64
stroke - etiology (63) 63
therapy (63) 63
myocardial-infarction (62) 62
cardiovascular diseases (61) 61
cardiac arrhythmia (60) 60
acute coronary syndrome (59) 59
cardiac patients (59) 59
clinical medicine (59) 59
heart failure (58) 58
patient outcomes (58) 58
acute coronary syndrome - drug therapy (57) 57
cardiovascular disease (57) 57
aspirin (56) 56
diabetes (54) 54
prevention (54) 54
cardiology and cardiovascular medicine (53) 53
heart attack (53) 53
percutaneous coronary intervention (53) 53
management (52) 52
ischemia (51) 51
anticoagulants - adverse effects (50) 50
rivaroxaban (50) 50
anticoagulants - administration & dosage (49) 49
internal medicine (49) 49
kardiologi (49) 49
cardiac and cardiovascular systems (48) 48
platelet aggregation inhibitors - adverse effects (48) 48
risk assessment (48) 48
klinisk medicin (47) 47
proportional hazards models (47) 47
randomized controlled trials as topic (47) 47
bleeding (46) 46
myocardial infarction - mortality (46) 46
ticlopidine - analogs & derivatives (46) 46
registries (45) 45
ticagrelor (45) 45
hospitalization (44) 44
myocardial infarction - therapy (44) 44
hemorrhage (43) 43
incidence (43) 43
medicine, general & internal (43) 43
studies (43) 43
coronary vessels (42) 42
myocardial infarction - drug therapy (41) 41
thrombosis (41) 41
research (39) 39
unstable angina (39) 39
anticoagulation (37) 37
administration, oral (36) 36
clinical outcomes (36) 36
medical colleges (36) 36
medical research (36) 36
usage (36) 36
warfarin - administration & dosage (36) 36
acute coronary syndrome - mortality (35) 35
dosage and administration (35) 35
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 1, pp. 32 - 40
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 382, Issue 9909, pp. 1981 - 1992
Journal Article
The American heart journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 682 - 689.e1
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 368, Issue 14, pp. 1303 - 1313
This clinical trial compared two antiplatelet regimens during PCI: oral clopidogrel and intravenous cangrelor. As compared with clopidogrel, cangrelor resulted... 
no | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | METAANALYSIS | TICAGRELOR | CARDIOVASCULAR EVENTS | ACHIEVE OPTIMAL MANAGEMENT | CLOPIDOGREL PRETREATMENT | PRASUGREL | STANDARD THERAPY | ANTIPLATELET THERAPY | STRATEGIES | Double-Blind Method | Ticlopidine - therapeutic use | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Adenosine Monophosphate - therapeutic use | Ticlopidine - analogs & derivatives | Adenosine Monophosphate - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Adenosine Monophosphate - analogs & derivatives | Hemorrhage - etiology | Intention to Treat Analysis | Myocardial Ischemia - therapy | Ticlopidine - adverse effects | Female | Aged | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Stents - adverse effects | Thrombosis - mortality | Platelet Aggregation Inhibitors - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Cangrelor | Angioplasty | Patient outcomes | Product/Service Evaluations | Hemorrhage | Risk factors | Control | Ischemia | Dosage and administration | Drug therapy | Myocardial infarction | Adenosine | Heart attacks | Intravenous administration | Thrombosis | Patients | Bleeding | Dyspnea | Implants | Clopidogrel | Acute coronary syndromes | Respiration
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 7, pp. 644 - 657
In this report of two randomized trials, patients with type 2 diabetes at risk for cardiovascular disease received the sodium–glucose cotransporter 2 inhibitor... 
METAANALYSIS | ATRIAL-NATRIURETIC-PEPTIDE | RATIONALE | INTENSIVE GLUCOSE CONTROL | PLACEBO-CONTROLLED TRIAL | OUTCOMES | INHIBITORS | STAGE KIDNEY-DISEASE | PROGRESSION | BASE-LINE CHARACTERISTICS | MEDICINE, GENERAL & INTERNAL | DESIGN | EMPAGLIFLOZIN | Hypoglycemic Agents - therapeutic use | Albuminuria - complications | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Kidney Diseases - mortality | Male | Canagliflozin - adverse effects | Disease Progression | Foot - surgery | Glomerular Filtration Rate - drug effects | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin - therapeutic use | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Aged | Amputation - statistics & numerical data | Kidney Diseases - etiology | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Heart | Complications and side effects | Care and treatment | Abnormalities | Amputation | Myocardial infarction | Heart attacks | Body weight | Clinical trials | Cardiovascular disease | Blood pressure | Drug dosages | Heart failure | Cerebral infarction | Stroke | Statistical analysis | Kidneys | Metatarsal | Diabetes mellitus | Toe | FDA approval | Glomerular filtration rate | Medicine | Studies | Side effects | Sodium | Diabetes | Kidney diseases | Cardiovascular diseases | Health risk assessment | Kidney transplantation
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 379, Issue 22, pp. 2097 - 2107
Among patients who had had an acute coronary syndrome, the risk of death from coronary heart disease, nonfatal myocardial infarction, stroke, or unstable... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | MYOCARDIAL-INFARCTION | TASK-FORCE | EFFICACY | SAFETY | LDL | REDUCING LIPIDS | PCSK9 | MONOCLONAL-ANTIBODY | ASSOCIATION | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Acute Coronary Syndrome - complications | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Cardiovascular Diseases - epidemiology | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Acute coronary syndrome | Diagnosis | Myocardial infarction | Fees & charges | Lipoproteins (low density) | Heart attacks | Lipids | Cardiovascular disease | Angina | Apolipoprotein B | Ischemia | Heart diseases | Drug dosages | Statins | Cerebral infarction | Stroke | Subtilisin | Angina pectoris | Patients | Low density lipoprotein | Coronary artery disease | Cholesterol | Kexin | Monoclonal antibodies | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Pharmaceuticals | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 1, pp. 20 - 33
In this trial, vorapaxar, a protease-activated–receptor 1 antagonist that inhibits thrombin-induced platelet activation, was not effective in reducing the... 
MEDICINE, GENERAL & INTERNAL | PLACEBO | GLYCOPROTEIN IIB/IIIA INHIBITORS | CLOPIDOGREL | TASK-FORCE | SAFETY | DOUBLE-BLIND | ANTIPLATELET THERAPY | Follow-Up Studies | Angioplasty | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Double-Blind Method | Receptor, PAR-1 - antagonists & inhibitors | Kaplan-Meier Estimate | Combined Modality Therapy | Lactones - adverse effects | Lactones - therapeutic use | Acute Coronary Syndrome - drug therapy | Intracranial Hemorrhages - chemically induced | Coronary Artery Bypass | Acute Coronary Syndrome - therapy | Aged | Hemorrhage - chemically induced | Antagonists (Biochemistry) | Drugs | Dose-response relationship (Biochemistry) | Dosage and administration | Product/Service Evaluations | Drug therapy | Coronary heart disease | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | Proteinase-activated receptor 1 | Thrombin | Cardiovascular disease | Hemorrhage | Bleeding | Investigations | Manuscripts | Ischemia | Blood platelets | Acute coronary syndromes | Research centers | Malalties cardiovasculars | Bypass cardiopulmonar | Medicaments | Bypass cardiopulmonary | Plaquetes sanguínies | Cardiovascular diseases
Journal Article